Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

被引：84

作者：

Lleo, Alberto ^{[1
,2
]}

Alcolea, Daniel ^{[1
,2
]}

Martinez-Lage, Pablo ^{[3
]}

Scheltens, Philip ^{[4
,5
]}

Parnetti, Lucilla ^{[6
]}

Poirier, Judes ^{[7
]}

Simonsen, Anja H. ^{[8
]}

Verbeek, Marcel M. ^{[9
,10
]}

Rosa-Neto, Pedro ^{[7
]}

Slot, Rosalinde E. R. ^{[4
,5
]}

Tainta, Mikel ^{[3
]}

Izaguirre, Andrea ^{[3
]}

Reijs, Babette L. R. ^{[11
]}

Farotti, Lucia ^{[6
]}

Tsolaki, Magda ^{[12
,13
]}

Vandenbergue, Rik ^{[14
,15
]}

Freund-Levi, Yvonne ^{[16
,17
]}

Verhey, Frans R. J. ^{[11
]}

Clarimon, Jordi ^{[1
,2
]}

Fortea, Juan ^{[1
,2
]}

Frolich, Lutz ^{[18
]}

Santana, Isabel ^{[19
,20
]}

Luis Molinuevo, Jose ^{[21
]}

Lehmann, Sylvain ^{[22
]}

Visser, Pieter J. ^{[4
,5
,11
]}

Teunissen, Charlotte E. ^{[4
,5
]}

Zetterberg, Henrik ^{[23
,24
,25
,26
]}

Blennow, Kaj ^{[23
,24
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain

[2] Ctr Biomed Invest Network Neurodegenerat Dis CIBE, Madrid, Spain

[3] Fdn CITA Alzheimer Fundazioa, Ctr Res & Adv Therapies, San Sebastian, Spain

[4] Vrije Univ Amsterdam, Med Ctr, Dept Neurol, Amsterdam UMC, Neurosci Campus Amsterdam, Amsterdam, Netherlands

[5] Vrije Univ Amsterdam, Med Ctr, Alzheimer Ctr, Neurosci Campus Amsterdam, Amsterdam, Netherlands

[6] Univ Perugia, Sect Neurol, Lab Clin Neurochem, Ctr Memory Disturbances, Perugia, Italy

[7] Douglas Mental Hlth Univ Inst, Ctr Studies Prevent Alzheimers Dis, Montreal, PQ, Canada

[8] Univ Copenhagen, Danish Dementia Res Ctr, Rigshosp, Copenhagen, Denmark

[9] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol,Radboud Alzheimer Ctr, Nijmegen, Netherlands

[10] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Lab Med,Radboud Alzheimer Ctr, Nijmegen, Netherlands

[11] Maastricht Univ, Alzheimer Ctr Limburg, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Maastricht, Netherlands

[12] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol 1, Macedonia, Greece

[13] Alzheimer Hellas, Thessaloniki, Greece

[14] Univ Hosp Leuven, Leuven, Belgium

[15] Katholieke Univ Leuven, Dept Neurosci, Lab Cognit Neurol, Leuven, Belgium

[16] Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Clin Geriatr, Huddinge, Sweden

[17] Kings Coll London, Dept Old Age Psychiat Psychol & Neurosci, London, England

[18] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Mannheim, Germany

[19] Ctr Hosp & Univ Coimbra, Dementia Clin, Coimbra, Portugal

[20] Univ Coimbra, Fac Med, Coimbra, Portugal

[21] ICN Hosp Clin & Univ, Barcelona, Spain

[22] Univ Montpellier, CHU Montpellier, Montpellier, France

[23] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Molndal, Sweden

[24] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden

[25] UCL, Dept Neurodegenerat Dis, Queen Sq, London, England

[26] UCL, UK Dementia Res Inst, London, England

来源：

ALZHEIMERS & DEMENTIA | 2019年 / 15卷 / 06期

基金：

瑞典研究理事会; 欧洲研究理事会;

关键词：

Alzheimer; CSF; Tau; Amyloid; Neurofilaments; Inflammation; YKL-40; NEUROFILAMENT LIGHT; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; CSF BIOMARKERS; TAU LEVELS; RECOMMENDATIONS; PROTEIN; BETA; DEMENTIA;

D O I：

10.1016/j.jalz.2019.01.015

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) are not well defined. Methods: We included 467 subjects from the BIOMARKAPD study with at least two serial CSF samples. Diagnoses were subjective cognitive decline (n = 75), mild cognitive impairment (n = 128), and AD dementia (n = 110), and a group of cognitively unimpaired subjects (n = 154) were also included. We measured baseline and follow-up CSF levels of total tau (t-tau), phosphorylated tau (p-tau), YKL-40, and neurofilament light (NfL). Median CSF sampling interval was 2.1 years. Results: CSF levels of t-tau, p-tau, NfL, and YKL-40 were 2% higher per each year of baseline age in controls (P <. 001). In AD, t-tau levels were 1% lower (P <. 001) and p-tau levels did not change per each year of baseline age. Longitudinally, only NfL (P <. 001) and YKL-40 (P <. 02) increased during the study period. Discussion: All four CSF biomarkers increase with age, but this effect deviates in AD for t-tau and ptau. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

引用

页码：742 / 753

页数：12

共 50 条

[41] SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease
Weiner, Sophia
Sauer, Mathias
Brinkmalm, Gunnar
Constantinescu, Julius
Constantinescu, Radu
Gomes, Barbara Fernandes
Becker, Bruno
Nellgard, Bengt
Dalla, Keti
Galasko, Douglas
Zetterberg, Henrik
Blennow, Kaj
Gobom, Johan
[J]. ALZHEIMERS & DEMENTIA, 2023, 19 (10) : 4609 - 4618
[42] The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease
Makitalo, Signar
Mellgren, Asa
Borgh, Ellen
Kilander, Lena
Skillback, Tobias
Zetterberg, Henrik
Gisslen, Magnus
[J]. AIDS RESEARCH AND THERAPY, 2015, 12
[43] Spatial correlation maps of the hippocampus with cerebrospinal fluid biomarkers and cognition in Alzheimer's disease: A longitudinal study
Liu, Guodong
Liu, Chaoqiang
Qiu, Anqi
[J]. HUMAN BRAIN MAPPING, 2021, 42 (09) : 2931 - 2940
[44] Cerebrospinal fluid biomarkers in Huntington's disease - a longitudinal study
Niemela, V.
Sundblom, J.
Landtblom, A. -M.
Herman, S.
Kultema, K.
Nyholm, D.
Blennow, K.
[J]. MOVEMENT DISORDERS, 2017, 32 (12) : E8 - E8
[45] Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease
Pirttilä, T
Koivisto, K
Mehta, PD
Reinikainen, K
Kim, KS
Kilkku, O
Heinonen, E
Soininen, H
Riekkinen, P
Wisniewski, HM
[J]. NEUROSCIENCE LETTERS, 1998, 249 (01) : 21 - 24
[46] Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease
Aichholzer, Freyja
Klafki, Hans-Wolfgang
Ogorek, Isabella
Vogelgsang, Jonathan
Wiltfang, Jens
Scherbaum, Norbert
Weggen, Sascha
Wirths, Oliver
[J]. ALZHEIMERS RESEARCH & THERAPY, 2021, 13 (01)
[47] The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer's disease diagnostic revolution
Schindler, Suzanne E.
Atri, Alireza
[J]. NATURE AGING, 2023, 3 (05): : 460 - 462
[48] Cerebrospinal fluid biomarkers in Huntington's disease - a longitudinal study
Niemela, V.
Sundblom, J.
Landtblom, A. -M.
Herman, S.
Kultema, K.
Nyholm, D.
Blennow, K.
[J]. MOVEMENT DISORDERS, 2017, 32
[49] Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease
van Harten, Argonde C.
Mulders, Joyce
Scheltens, Philip
van der Flier, Wiesje M.
Oudejans, Cees B. M.
[J]. JOURNAL OF ALZHEIMERS DISEASE, 2015, 47 (01) : 243 - 252
[50] The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer’s disease
Signar Mäkitalo
Åsa Mellgren
Ellen Borgh
Lena Kilander
Tobias Skillbäck
Henrik Zetterberg
Magnus Gisslén
[J]. AIDS Research and Therapy, 12

← 1 2 3 4 5 →